Metformin: A Possible Option in Cancer Chemotherapy
Metformin has been used for a long time as an antidiabetic medication for type 2 diabetes. It is used either as a monotherapy or in combination with other antidiabetic medications. The drug came into prominence in diabetes and other conditions with cardiovascular risk after the landmark study of 199...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2020/7180923 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557123083436032 |
|---|---|
| author | Chidiebere V. Ugwueze Odunze J. Ogamba Ekenechukwu E. Young Belonwu M. Onyenekwe Basil C. Ezeokpo |
| author_facet | Chidiebere V. Ugwueze Odunze J. Ogamba Ekenechukwu E. Young Belonwu M. Onyenekwe Basil C. Ezeokpo |
| author_sort | Chidiebere V. Ugwueze |
| collection | DOAJ |
| description | Metformin has been used for a long time as an antidiabetic medication for type 2 diabetes. It is used either as a monotherapy or in combination with other antidiabetic medications. The drug came into prominence in diabetes and other conditions with cardiovascular risk after the landmark study of 1995 by the United Kingdom Prospective Diabetes Study which emphasized its importance. However, the drug has been used in experimental trials in various aspects of medicine and pharmacology such as in reproductive medicine, cancer chemotherapy, metabolic diseases, and neurodegenerative diseases. It has been in use in the treatment of polycystic ovarian disease and obesity and is being considered in type 1 diabetes. This study seeks to evaluate the relevance of metformin in cancer management. Different mechanisms have been proposed for its antitumor action which involves the following: (a) the activation of adenosine monophosphate kinase, (b) modulation of adenosine A1 receptor (ADORA), (c) reduction in insulin/insulin growth factors, and (d) the role of metformin in the inhibition of endogenous reactive oxygen species (ROS); and its resultant damage to deoxyribonucleic acid (DNA) molecule is another paramount antitumor mechanism. |
| format | Article |
| id | doaj-art-b3eb2e006f364f40be17adab340baf5f |
| institution | Kabale University |
| issn | 2210-7177 2210-7185 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Analytical Cellular Pathology |
| spelling | doaj-art-b3eb2e006f364f40be17adab340baf5f2025-02-03T05:43:41ZengWileyAnalytical Cellular Pathology2210-71772210-71852020-01-01202010.1155/2020/71809237180923Metformin: A Possible Option in Cancer ChemotherapyChidiebere V. Ugwueze0Odunze J. Ogamba1Ekenechukwu E. Young2Belonwu M. Onyenekwe3Basil C. Ezeokpo4Ebonyi State University, Abakaliki, NigeriaEbonyi State University, Abakaliki, NigeriaUniversity of Nigeria Teaching Hospital, Enugu, NigeriaUniversity of Nigeria Teaching Hospital, Enugu, NigeriaEbonyi State University, Abakaliki, NigeriaMetformin has been used for a long time as an antidiabetic medication for type 2 diabetes. It is used either as a monotherapy or in combination with other antidiabetic medications. The drug came into prominence in diabetes and other conditions with cardiovascular risk after the landmark study of 1995 by the United Kingdom Prospective Diabetes Study which emphasized its importance. However, the drug has been used in experimental trials in various aspects of medicine and pharmacology such as in reproductive medicine, cancer chemotherapy, metabolic diseases, and neurodegenerative diseases. It has been in use in the treatment of polycystic ovarian disease and obesity and is being considered in type 1 diabetes. This study seeks to evaluate the relevance of metformin in cancer management. Different mechanisms have been proposed for its antitumor action which involves the following: (a) the activation of adenosine monophosphate kinase, (b) modulation of adenosine A1 receptor (ADORA), (c) reduction in insulin/insulin growth factors, and (d) the role of metformin in the inhibition of endogenous reactive oxygen species (ROS); and its resultant damage to deoxyribonucleic acid (DNA) molecule is another paramount antitumor mechanism.http://dx.doi.org/10.1155/2020/7180923 |
| spellingShingle | Chidiebere V. Ugwueze Odunze J. Ogamba Ekenechukwu E. Young Belonwu M. Onyenekwe Basil C. Ezeokpo Metformin: A Possible Option in Cancer Chemotherapy Analytical Cellular Pathology |
| title | Metformin: A Possible Option in Cancer Chemotherapy |
| title_full | Metformin: A Possible Option in Cancer Chemotherapy |
| title_fullStr | Metformin: A Possible Option in Cancer Chemotherapy |
| title_full_unstemmed | Metformin: A Possible Option in Cancer Chemotherapy |
| title_short | Metformin: A Possible Option in Cancer Chemotherapy |
| title_sort | metformin a possible option in cancer chemotherapy |
| url | http://dx.doi.org/10.1155/2020/7180923 |
| work_keys_str_mv | AT chidieberevugwueze metforminapossibleoptionincancerchemotherapy AT odunzejogamba metforminapossibleoptionincancerchemotherapy AT ekenechukwueyoung metforminapossibleoptionincancerchemotherapy AT belonwumonyenekwe metforminapossibleoptionincancerchemotherapy AT basilcezeokpo metforminapossibleoptionincancerchemotherapy |